<SEC-DOCUMENT>0001104659-21-103476.txt : 20210811
<SEC-HEADER>0001104659-21-103476.hdr.sgml : 20210811
<ACCEPTANCE-DATETIME>20210811161620
ACCESSION NUMBER:		0001104659-21-103476
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20210811
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210811
DATE AS OF CHANGE:		20210811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		211163611

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2124843d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event reported):
August 11, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>0-50626</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>91-1707622</B></FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: center; vertical-align: top"><B>(State or other jurisdiction<BR>
 of
    incorporation)</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top"><B>(IRS Employer<BR>
 Identification No.)</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>200 Connell Drive, Suite 1500</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Berkeley Heights, NJ 07922</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive offices and
zip code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&#8217;s telephone number, including
area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former Name or Former Address, if Changed Since
Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see
</I>General Instruction A.2. below): </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Securities registered pursuant
to Section&nbsp;12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 97%; border-collapse: collapse; margin-left: 0.25in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 40%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 20%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 40%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name of each exchange on which registered </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Common Stock, par value $0.001 per share</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CYCC</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Preferred Stock, $0.001 par value</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CYCCP</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Emerging growth company&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px"><FONT STYLE="font-size: 10pt"><B>Item 2.02</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Results of Operations and Financial Condition.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information set forth
under this &#8220;Item 2.02. Results of Operations and Financial Condition,&#8221; including the exhibit attached hereto, shall not be
deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated
by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference
in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Attached as Exhibit 99.1 is
a copy of a press release of Cyclacel Pharmaceuticals, Inc. (the &#8220;<B>Company</B>&#8221;), dated August 11, 2021, announcing certain
financial results for the second quarter ended June 30, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will conduct a
conference call to review its financial results on August 11, 2021, at 4:30 p.m., Eastern Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Financial Statements and Exhibits.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Exhibits.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 50pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm2124843d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="text-align: justify"><A HREF="tm2124843d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press release announcing financial results for the second quarter ended
    June 30, 2021, dated August 11, 2021.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Paul McBarron</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Paul McBarron</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President&#8212;Finance,</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer and Chief Operating Officer</FONT></TD>
    </TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 11, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2124843d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left"><IMG SRC="image_001.jpg" ALT=""></TD><TD STYLE="vertical-align: middle; text-align: right; width: 50%">Cyclacel
                                            Pharmaceuticals, Inc.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: rgb(163,163,163) 1pt solid; padding-bottom: 5pt; text-align: center; width: 100%"><IMG SRC="image_002.jpg" ALT=""></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Cyclacel
Pharmaceuticals Reports SECOND Quarter 2021 Financial Results </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AND
PROVIDES BUSINESS UPDATE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><I>- Announces First
Patients with Solid Tumors Dosed with Oral Fadraciclib -</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><I>- Additional Phase
1/2 Trials for Fadraciclib and CYC140 Expected to Follow -</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><I>- Cash Runway to
Early 2023 -</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><I>- Conference Call
Scheduled August 11, 2021 at 4:30 p.m. ET -</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 174.25pt; text-align: center; text-indent: -2.3in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Berkeley Heights, NJ, August 11, 2021
</B>- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &quot;Cyclacel&quot; or the &quot;Company&quot;), a biopharmaceutical
company developing innovative medicines based on cancer cell biology, today reported its financial results for the second quarter 2021.
The quarter&rsquo;s business highlights included an update on the Company&rsquo;s progress with fadraciclib and CYC140, Cyclacel's novel
CDK2/9 and PLK1 inhibitors, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;After announcing In July that the
first patient had been dosed with oral fadraciclib, two additional patients with advanced solid tumors have been treated, completing
enrolment of the first dose level,&rdquo; said Spiro Rombotis, President and Chief Executive Officer. &ldquo;We are encouraged by investigator
interest in our fadraciclib 065-101 solid tumor study. In earlier clinical studies fadraciclib has demonstrated single-agent activity,
including durable PR. We believe that fadraciclib is a leading, transcriptionally-active CDK inhibitor with a differentiated product
profile. Pipeline momentum will continue to build with the planned opening of protocol 065-102, an oral fadraciclib study in patients
with hematological malignancies, and later with the initiation of two similar protocols in solid tumors and hematological malignancies
for our novel PLK1 inhibitor, CYC140. The second half of 2021 is an exciting period for Cyclacel, as we expand our clinical programs
and increase our visibility as an oncology leader focused on cell cycle inhibition for the treatment of cancer. We look forward to reporting
further updates as data from these studies become available.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Key Corporate Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Oral
                                            fadraciclib - </B>First three patients with advanced solid tumors dosed in the 065-101 Phase
                                            1/2, registration-directed trial. The study includes multiple cohorts defined by histology
                                            thought to be sensitive to the drug&rsquo;s mechanism of action and informed by the clinical
                                            activity of fadraciclib in MCL1, MYC and/or cyclin E amplified cancers. The cohorts include
                                            breast (<FONT STYLE="background-color: white">metastatic, hormone receptor positive, post-CDK4/6
                                            inhibitor; HER-2 refractory; or triple negative)</FONT>, cholangiocarcinoma, colorectal (including
                                            KRAS mutant), endometrial, hepatocellular, ovarian cancers and certain lymphomas. The study
                                            design also includes a basket cohort which will enroll patients with relevant biomarkers
                                            to the drug&rsquo;s mechanism regardless of histology. Previously single agent, intravenous
                                            fadraciclib has demonstrated durable suppression of MCL1 and other mechanistically-related
                                            proteins, including cyclin E and MYC, at tolerated doses. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Oral
                                            CYC140 </B>&ndash; continued progress with IND-directed activities and manufacturing of clinical
                                            trial supplies. Initial data in preclinical models show that KRAS mutant cancers are sensitive
                                            to oral CYC140 inhibition. The Company expects to begin a study in patients with solid tumors
                                            in the second half of 2021. Similar to the fadraciclib clinical program, the CYC140 Phase
                                            1/2 study will be a registration-directed trial using a streamlined design that will first
                                            determine the</FONT> recommended Phase 2 dose (RP2D) for single-agent CYC140.
Once the RP2D has been established, the trial will immediately enter into a proof-of-concept, cohort stage, using a Simon 2-stage design,
where single agent CYC140 will be administered to patients across multiple cohorts based upon those histologies thought to be sensitive
to the drug&rsquo;s mechanism of action.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 8pt Wingdings">&thorn;</FONT><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;&nbsp;200
Connell Drive, Suite 1500, Berkeley Heights, NJ 07922, USA Tel +1 908 517 7330 Fax +1 866 271 3466</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><U>www.cyclacel.com </U>&ndash; <U>info@cyclacel.com</U></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Key Near-Term Business Objectives and Expected Timeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"><B>2H 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">First
                                            patient to be dosed with oral fadraciclib in 065-102 Phase 1/2 leukemia study</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">FDA
                                            clearance of IND filing; begin oral CYC140 Phase 1/2 advanced solid tumor study </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"><B>1H 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">First
                                            patient to be dosed with oral CYC140 in Phase 1/2 leukemia study</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Phase
                                            1 data with oral fadraciclib in advanced solid tumor 065-101 study </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.7pt 0pt 0"><B>Financial Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">As of June 30, 2021, cash and cash equivalents
totaled $43.6 million, compared to $47.8 million as of March 31, 2021. The decrease of $4.2 million was primarily due to net cash used
in operating activities. The Company estimates that the cash resources will fund currently planned programs through early 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $4.1 million for the three
months ended June 30, 2021 as compared to $1.2 million for the same period in 2020. Research and development (R&amp;D) expenses relating
to fadraciclib increased by approximately $1.9 million for the three&nbsp;months ended June 30, 2021 with the start of the CYC065-101
study of fadraciclib in solid tumors and preparations for opening the 065-102 study of fadraciclib in leukemias. Additionally, R&amp;D
expenses related to CYC140 increased $1.0 million for the quarter as IND-directed activities are approaching completion and clinical
trial supplies are being manufactured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">General and administrative expenses for the three months ended June
30, 2021 were $2.0 million, compared to $1.3 million for the same period of the previous year due to costs of approximately $0.4 million
related to exiting a long-term facility lease, increased legal and professional expenses and recruitment costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">United Kingdom research &amp; development
tax credits were $1.0 million for the three months ended June 30, 2021, as compared to $0.3 million for the same period in 2020 due to
the increase in R&amp;D expenditure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Net loss for the three months ended June
30, 2021 was $5.1 million, compared to $2.2 million for the same period in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Conference call information:
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conference ID: CYCCQ221</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">US&nbsp;call: (866) 342-8591/
international call: +1 (203) 518-9713&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Replay: US: (800) 839-5109
/ international archive: +1 (402) 220-2688</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Code for live and replay conference call
is CYCCQ221 <U>Webcast link</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">For the live and archived webcast, please
visit the Corporate Presentations page on the&nbsp;Cyclacel&nbsp;website at <U>www.cyclacel.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Cyclacel <FONT STYLE="background-color: white">is
a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and
mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program CYC140,
a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies.&nbsp;</FONT>Cyclacel's<FONT STYLE="background-color: white">&nbsp;strategy
is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology
indications. For additional information, please visit </FONT><U>www.cyclacel.com</U><FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This news release contains
certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from
historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements
include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the
conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared
promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials
may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance
on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical
trials, development and commercialization of product candidates. You are urged to consider statements that include the words &quot;may,&quot;
&quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;believes,&quot; &quot;estimates,&quot; &quot;projects,&quot;
&quot;potential,&quot; &quot;expects,&quot; &quot;plans,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot;
&quot;designed,&quot; &quot;goal,&quot; or the negative of those words or other comparable words to be uncertain and forward-looking.
For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on
Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at <U>www.sec.gov</U>.
Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.4in">Company:</TD>
  <TD>Paul McBarron, (908) 517-7330, <U>pmcbarron@cyclacel.com</U></TD></TR>

<TR STYLE="vertical-align: top">
  <TD>Investor Relations:</TD>
  <TD>LifeSci Advisors, LLC, Irina Koffler, (646) 970-4681, <U>ikoffler@lifesciadvisors.com</U></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&copy; Copyright 2021 Cyclacel Pharmaceuticals, Inc. All Rights Reserved.
The Cyclacel logo and Cyclacel&reg; are trademarks of Cyclacel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS (LOSS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In $000s, except share and per share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Revenues:</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,163</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">4,101</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,309</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,999</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,472</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,472</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(6,100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income (expense):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Foreign exchange gains (losses)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(13</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other income, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">18</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">18</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Total other income (expense), net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Loss before taxes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,452</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(6,091</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Income tax benefit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">286</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">964</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,166</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,127</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend on convertible exchangeable preferred shares</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(50</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(50</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Beneficial conversion feature of Series B preferred stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss applicable to common shareholders</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,216</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,177</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Basic and diluted earnings per common share:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss per share &ndash; basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.58</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.56</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Weighted average common shares outstanding</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,850,228</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,234,110</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SOURCE: Cyclacel Pharmaceuticals, Inc</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED BALANCE SHEET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In $000s, except share, per share, and liquidation
preference amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">ASSETS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">33,406</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">43,639</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,063</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,564</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Total current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">35,469</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46,203</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">106</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">73</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Right-of-use lease asset</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,227</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">58</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">36,802</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">46,334</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">514</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,197</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Accrued and other current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,972</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,921</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Total current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,486</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,118</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left; padding-bottom: 1pt">Lease liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,057</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,543</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,118</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Stockholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">33,259</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">43,216</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">36,802</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">46,334</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SOURCE: Cyclacel Pharmaceuticals, Inc</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !, ,@# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_7)R< \
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MAE;77/'>MQ;"!.-,A:*#0K"1V!_M?Q+?Z5ITHBECM'N+KRK>7\)_C'_P7/\
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MV3D=3N*ESP,D$AN,C)W @8(- $M%0&= .0X!(4,48+EB54[F 49884$Y8E0
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MGG//)YZYI0ZMT(..N#T[>U.JMM//\?3SMV1K\G?SO?YWU_KJ>+_M$?&[P/\
MLU?!#XL?M!?$S4I]*^'?P5^'/C+XG^-KJR6QEU-O#G@K0+_7+ZTT2UU&\T^S
MO]?U%;5=.T'2Y[ZS75-9NK"P%S&TZAOYA/V,/V?/V_?^"Y'PPB_;>_;D_;+_
M &AOV0_V9OC%/J%_^S3^QE^PMX_T_P"%$<7PMTKQ#-'HOB[XN_%*;1_$'B+Q
M9J/B6>UO;%K=M*LM=O+.WMO$UEJ7@K2=7LO!>D_N+_P5Z^"/CW]H[_@F7^V[
M\%?A;IC:[\1_'?[._P 0;/P7X=AM[N[O_$^O:3IZ>([+PMHUK86]W>76O^)F
MT8Z%X?M(H&2[UN_T^&>2&)FFC^5O^#>+]K+X6_M3?\$KOV5;7X?ZYH,WBKX!
M?"_PQ\ _B_X)T^2.VUGP'XZ^'.G+H,(UG13++=6EKXPT2QT_Q9HE_(/LVIVN
MH3&"0W5KJ%M9@#]._P""+6E>#/@1^U%\ O /[>'_  4%N/#7[0'@/3]+\!/\
M5OVAM=\?ZA^SC\2_#>HWNL^$_B!\(/&-A8^%_&>E6+:FUE9>,_#.J:]JS^*_
M#]H-*FU:PMIH1%X#_P $?/\ @IGXHL/V5/VE_@+_ ,%(_%]M\/OVLO\ @D\F
MO^%/VJ]6\1WQO+GQ/\&O"ND3ZMX!^.(U<M=V_B:X\1>';"[T*\N]*O[^Z\2Z
MKI>C^*(X8/\ A/='M)OZ/Y &78Q W#'8YXZ '[WTP<C@@@D5_&'_ ,'#7['W
MPA^(7_!47_@DK+??\)-X=3]N[XD:-^R/^UM9^#-?N?#-G\<O@5X#^+?P?^(O
MASPGXXM]/5$UJ2UU]K13J%]]HNYK;0?!T9D$O@KPM+I(!]!_L.?M"?%;1?@U
M^WG_ ,'$'[<NL?%/0/A)XZ\%Z]XA_8P_94D\=ZE8^%O G[*WA)ET_P"&EQ;>
M#6UI_!H^*?[06K1^%-"TWQ+J6CVES<W%Q?>*-+6W\/>/K&UM4_8^_8H_;?\
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M]15Z[^K4:=:EE>5\54\MHXK$\-<3X# U9Y?A<ZGE>)R3B3+)J4J&9931P/\
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M<OXF?M'?\$!?V&_CW\:/$_[2'@;6_P!HK]B_X_\ CNXDN_'WQ:_8>^,]_P#
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M#Z#^5 Z#Z"OGDM+^GY?U_2/T.UOR[_U]PM%%%, HHHH **** "BBB@ HHHH
..**** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  5 9 # 2(  A$! Q$!_\0
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4LN[D 1//*P*!"2YW$@  HH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
